~ Abnormal Bleeding ~
¡@
Causes of Bleeding by Approximate Frequency and Age Group
Prepubertal |
|
Adolescent |
|
Reproductive |
|
Perimenopausal |
|
Postmenopausal |
|
¡@
Prepubertal Age Group
Vulvar and external |
|
Vaginal |
|
Uterine |
|
Ovarian tumor |
¡@ |
Exogenous estrogens |
|
¡@
- Vulvar irritation: pruritis with excoriation, maceration of the vulvar skin, or fissures.
- Urethral prolapse: a mass symmetrically surrounding the urethra
- Vaginal discharge, shich may appear purulent or bloody
- Rectal examination: An object can sometimes be palpated.
- Ultrasound should be the first study performed
- others: MRI, CT (rarely indicated)
- The prepubertal uterus has a distinctive appearance, with equal proportions of cervix and fundus
and a size of approximately 2-3.5 cm in length and 0.5-1 cm in width.
- Skin lesions: a shout course of topical mild steroids.
- Urethral prolapse: topical estrogens
- Vaginal / ovarian tumors: à gynecologic oncologists.
¡@
Adolescence
- During the first 2 years after menarche, most cycles are anovulatory
- Conditions considered out of the ordinary, particularly after the first 2 years after menarche:
1. Anovulation:
¡± Conditions associated with anovulation:
Eating disorders: anorexia nervosa, bulimia nervosa
Excessive physical exercise
Chronic illness
Alcohol and other drug abuse
Stress
Thyroid diseases: hypothyroidism, hyperthyroidism
DM
Androgen excess syndrome
¡± Anovulatory bleeding can be too frequent, prolonged or heavy, particularly after a long interval
of amenorrhea.
2. Pregnancy-related bleeding: eg. spontaneous abortion, ectopic pregnancy, molar pregnancy, etc.
3. Exogenous hormones: eg. oral contraceptives, missed pills, Norplant, etc
4. Hematologic abnormalities:
¡± most common: idiopathic thrombocytopenic purpura
¡± followed by: Willebrand¡¦s disease
5. Infections:
¡± Adolescents have the highest risks of PID and chlamydial infections of any age group.
6. Other endocrine or systemic problems: eg. thyroid dysfunction, PCOS, etc.
7. Anatomic causes:
- Sensitive pregnancy test:
- Laboratory testing:
¡± CBC with coagulation studies and bleeding time, cultures for gonorrhea, tests for chlamydia
infection, thyroid studies, etc.
- Imaging studies: ultrasound, etc.
- based on the appropriate diagnosis
(eg. pregnancy, thyroid dysfunction, hepatic abnormalities, hematologic abnormalities,
or androgen excess syndrome)
- In the absence of specific diagnosis, the assumption is that of anovulation or dysfunction bleeding.
- Mildly bleeding and mildly anemic:
¡± reassurance, close follow-up, supplemental iron
¡± hormonal therapy: (for 3-6 cycles)
? low-dose oral contraceptives: (eg. Nordette)
21-days hormonally active pills, followed by 7-days placebo, during which time
withdrawal bleeding is expected.
‚ cyclic progestins are an alternate:
provera (5) 5-10 mg qd for 10-13 days
to prevent excessive endometrial building and irregular shedding caused
by unopposed estrogen stimulation
- Acute bleeding: moderate:
¡± hormone therapy with highter dose than oral contraceptive:
then tapered or stopped to allow withdrawal bleeding
¥
Patient and her family should be warned about:Side effects: nausea, breast tenderness, and breakthrough bleeding
Heavy withdrawal flow for the first period
- Acute bleeding: emergency management:
¡± hospitalization: based on the rate of bleeding and the severity of anemia
¡± for bleeding:
¡± If DUB is diagnosed after excluding other systemic or organic diseases,
ð hormonal therapy
- conjugated estrogens:
? premarin (25) 25-40 mg v. q6h
‚ premarin (1.25) 2.5 mg po q6h
¤ If hormonal therapy fails, a local cause of bleeding is likely.
- oral progestin for several days:
withdrawal bleeding
- low-dose oral contraceptive for 3-6 cycles
¡± For patients with coagulopathies or malignancy requiring chemotherapy,
Ø long-term hormonal suppression of menstruation: (There are 4 choices.)
- continuous progestin: (eg. provera)
- continuous combination regimens of oral estrogen and progestins that do not include a withdrawal bleeding-placebo week
- depo-provera m., with or without concurrent estrogens
- GnRH analog
¡@
Reproductive Age Group
? Definition: abnormal bleeding for which no specific cause has been found
‚ most often implying a mechanism of anovulation
ƒ a diagnosis of exclusion
« Relatively low levels of estrogen stimulation will result in irregular and prolonged bleeding,
wherease higher sustained levels result in episodes of amenorrhea followed by acute heavy
bleeding.
? oral contraceptive:
- during the first1-3 month, 20-40% of women have breakthrough bleeding
à expectant management
‚ Norplant
ƒ depo-provera
« Non-hormonal cause should be considered, eg. chlamydial cervicitis.
eg. hyperthyroidism, hypothyroidism, DM, etc.
eg. myoma, endometrial polyp, cervical lesions, endocervical polyp, infectious cervical lesions,
eversion of endocervical columnar epithelium, Nabothian cyst, etc.
eg. cervicitis particularly chlamydial cervicitis, endometritis, etc.
À pregnancy test
Á CBC: to detect anemia or thrombocytopenia
 PT, PTT, BT (helpful on diagnosis of Willebrand¡¦s disease)
- Ultrasound is most useful.
- Cervical Biopsy: for cervical lesions
- Endometrial sampling (D&C): for endometrial polyps, hyperplasia or carcinoma.
À NSAID: Ponstan and Brufen have been shown to decrease menstrual flow by 30-50%.
Á Hormonal therapy:
a). low-dose oral contraceptive (eg. Nordette)
b). progestins: for women who are not suited for estrogen
- provera (5) 10 mg qd for 10 days per month
- depo-provera
- reserved for situations in which medical therapy fails or is contraindiated
- D&C
- others: hysteroscopy with resection of submucous myoma, laparoscopic myomectomy,
hysterectomy, etc.
¡@
¡@
Postmenopausal Women
Factor |
Approximate Percentage |
Exogenous estrogens |
30% |
Atrophic endometritis/vaginitis |
30% |
Endometrial cancer |
15% |
Endometrial or cervical polyps |
10% |
Endometrial hyperplasia |
5% |
Miscellaneous (eg. cervical cancer, uterine sarcoma, urethral caruncle, trauma) |
¡@ 10% |
À HRT-related problems: eg. poor compliance
Á atrophic vaginitis
 cervical polyps
à endocervical polyps and others
Ovarian, endometrial, or cervical malignancy
history, pelvic examination, pelvic ultrasound, biopsy, etc.
¬ atrophic vaginitis (diagnosed by exclusion?)
ã topical or systemic use of estrogen
cervical polyp: ã polypectomy
® others: see other files
¡@
Filename: Abnormal Bleeding
¡@